Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Novartis and Novo Nordisk see two cardiovascular drug candidates fail in trials

8 November 2026 · By · Wire by Fusion42

Published

8 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at dongascience.com →

◆ Verified

Fusion42 · 8 November 2026 · Fusion42 review

Novartis and Novo Nordisk's cardiovascular drug candidates, pelacarsen and ziltivekimab, respectively, failed to show efficacy in reducing cardiovascular events in detailed clinical trials presented at the American Heart Association sessions. The trials showed no advantage over placebo, challenging the hypotheses on targeting lipoprotein(a) and inflammation for cardiovascular disease prevention.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Cardiovascular drug progress has hit a dead-end. You developing therapies targeting lipoprotein(a) or inflammation should rethink your approach or patient focus immediately.

◆ Coverage

1 source · 8 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcardiovascularclinical-trialsdrug-failurenovartisnovo-nordisk